What happened. View real-time stock prices and stock quotes for a full financial overview. Over the past month, the Zacks Consensus EPS estimate has moved 10.38% higher. DVAX is currently sporting a Zacks Rank of #3 (Hold). View Novavax, Inc. NVAX investment & stock information. DVAX : 9.14 (+7.53%) The report will be for the fiscal Quarter ending Dec 2020. DVAX Dividend History & Description — Dynavax Technologies Corp Dynavax Technologies is a biopharmaceutical company focused on developing and commercializing vaccines. EMERYVILLE, Calif. (AP) — Dynavax Technologies Corp. (DVAX) on Thursday reported a loss of $15.5 million in its fourth quarter. On average, this group has gained an average of 10.48% so far this year, meaning that DVAX is performing better in terms of year-to-date returns. This compares to loss of $0.63 per share a year ago. So far today approximately 56,000 shares have been exchanged, as compared to an average 30-day... From Comtex SmarTrend® News Briefs Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. The best long-term & short-term ObsEva SA. The stock has a market cap of $1.04 billion, a P/E ratio of -6.92 and a beta of 1.34. ... From Zacks Investment Research Feb 26, 2021 Zacks Investment Research Celldex Therapeutics (CLDX) Analyst Forecast Next 12 months MEAN $34.33 +29.46% HIGH $36.00 +35.75% LOW $32.00 +20.66% Current Price $26.52 52-week … Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report To read this article on Zacks.com click here. myMotherLode.com - Responsive Dev - The Mother Lode's Local News, Sports, Weather, Movies, Classifieds, Yellow Pages, Real Estate Shares of Dynavax Technologies (NASDAQ:DVAX) traded at a new 52-week high today of $32.27. ET by Tomi Kilgore Verastem's stock was up 3.3% prior to trading halt The biotech didn't report any … Dynavax Technologies Corporation DVAX was a big mover last session, as the company saw its shares rise more than 9% on the day. On the other hand, the stock currently carries a Zacks … This group has a Zacks Industry Rank of 73, putting it … According to 4 analysts, the average rating for DVAX stock is "Strong Buy." ObsEva SA. That … It considers technical and fundamental factors and is a good starting point for evaluating a stock. View detailed financial information, real-time news, videos, quotes and analysis on Dynavax Technologies Corporation (NASDAQ:DVAX). These figures are adjusted for non-recurring items. Today, you can download 7 Best Stocks for the Next 30 Days. Who this matters to: Overall Ranking is a comprehensive evaluation. The move came on solid volume too with far more shares changing hands than in a normal session. Etsy stock was the second-best S&P 500 stock of 2020, behind only Tesla , by virtue of quadrupling across the year. This stock, which remained volatile and traded within the range of $2.6000 –$3.5900 in the past one-month time frame, witnessed a sharp increase yesterday. For Dynavax Technologies, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. Get the latest Novavax, Inc. NVAX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Want the latest recommendations from Zacks Investment Research? Two analysts have provided estimates for Dynavax Technologies’ earnings. Investors in Dynavax Technologies Corporation DVAX need to pay close attention to the stock based on moves in the options market lately. Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Verastem stock price target cut to $6 from $12 at Raymond James Mar. Dynavax Technologies Corp. Stock Price Forecast, "DVAX" Predictons for2021 One stock that might be an intriguing choice for investors right now is Dynavax Technologies Corporation DVAX. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.24. The Medical - Biomedical and Genetics industry is part of the Medical sector. For the Dynavax Technologies Corp forecast (traded under symbol DVAX) for one year forward price target at the top of this page, we have presented the average DVAX forecast for forward target price across the 3 analysts covering DVAX, as reported in data provided by Zacks … Check out our DVAX stock analysis, current DVAX quote, charts, and historical prices for Dynavax Technologies stock. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report To read this article on Zacks.com click here. EMERYVILLE, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Thursday reported a loss of $15.5 million in its fourth quarter.The Emeryville, California-based company said it had a loss of 14 cents per share.The results exceeded Wall Street expectations. DVAX | Complete Dynavax Technologies Corp. stock news by MarketWatch. It almost certainly won't match that in … 14, 2019 at 10:07 a.m. Find real-time BIDU - Baidu Inc stock quotes, company profile, news and forecasts from CNN Business. Price Target Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Based on 4 analysts offering 12 month price targets for Dynavax in the last 3 months. Zacks Equity Research - ZACKS - Thu Feb 25, 10:13AM CST Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. DVAX is holding a Zacks Rank of #3 (Hold) right now. What this means: Aldeyra Therapeu (ALDX) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 81 means that our comprehensive methodology rates Aldeyra Therapeu above 81% of stocks. Do the numbers hold clues to what lies ahead for the stock? Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. The average price target is $16.67 with a high forecast of $20.00 and a low forecast of $14.00.The average price target represents a 96.12% increase from the last price of $8.50. ... Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. The 12-month stock price forecast is 18.00, which is an increase of 96.94% from the latest price. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Dynavax Technologies (DVAX) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. ... Heatwave 'replay' forecast for start of summer. Today, you can download 7 Best Stocks for the Next 30 Days. To break things down more, DVAX belongs to the Medical - Biomedical and Genetics industry, a group that includes 381 individual companies and currently sits at #56 in the Zacks Industry Rank. Stock Forecast, OBSV stock price prediction. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Want the latest recommendations from Zacks Investment Research? Dynavax (DVAX) was a big mover last session, with shares rising over 6% on the day. This has resulted in an Earnings ESP of +3.23%. Wall Street brokerages forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will report sales of $13.20 million for the current quarter, according to Zacks Investment Research. Shares of Dynavax (NASDAQ:DVAX) were skyrocketing 30.2% higher as of 3:47 p.m. EDT on Monday. The lowest sales estimate is $11.17 million and the highest is $15.22 million. Shares of DVAX opened at $9.48 on Thursday.